Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial

Completed

Phase 4 Results

Results

Donepezil (10 mg/day) improved global aphasia severity (AQ of the WAB) relative to placebo. Picture naming subtest of the PALPA improved more with donepezil than with placebo.